Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. (AMLX) Revenue
Annual & quarterly revenue history · segment & region breakdown
AMLX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAmylyx Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.09B | -100.00% |
| 2024-12-31 | $0.09B | -$0.29B | -77.06% |
| 2023-12-31 | $0.38B | +$0.36B | +1612.94% |
| 2022-12-31 | $0.02B | +$0.02B | — |
| 2021-12-31 | $0.00B | -$0.00B | -100.00% |
| 2020-12-31 | $0.00B | -$0.00B | -54.42% |
| 2019-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare AMLX revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Amylyx Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Amylyx Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Amylyx Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AMLX revenue · 4 questionsAMLX's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Amylyx Pharmaceuticals, Inc. SEC filings · GAAP · Amylyx Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026